公开(公告)号：EP1267908A1

公开(公告)日：2003-01-02

申请号：EP01919363.0

申请日：2001-03-01

申请人： SMITHKLINE BEECHAM BIOLOGICALS S.A.

发明人： FRUCHART, Jean-Charles,Institut Pasteur de Lille ,  MONTEYNE, Philippe,GlaxoSmithKline ,  PALMANTIER, Remi,GlaxoSmithKline ,  VAN MECHELEN, Marcelle, Paulette,GlaxoSmithKline

IPC分类号： A61K38/17

CPC分类号： A61K39/0012 ,  A61K2039/55577 ,  A61K2039/6081

摘要： Novel vaccine therapies, and prophylactic treatments of atherosclerotic diseases involving use of immugones comprising apolipoproteins, or fragments thereof, having at least one of the following activities: (a) the inhibition of the binding of Apolipoprotein B to its receptor, and, or, (b) the inhibition of lipoprotein lipase. A preferred example of one such apolipoprotein is Apolipoprotein C-III (ApoCIII). The vaccines of the present invention, comprising said immunogens, prevent atheroslerosis plaque formation, thereby reducing coronary or cerebrovascular disease. Artherosclerosis is also treated by selectively inhibiting the activity of specific apolipoproteins e.g. ApoCIII in a human, comprising administering an agent which results in the selective inhibition of the apolipoprotein activity to a human. Atherosclerosis is also treated by active or passive vaccination, by administering an antibody that is capable of binding to a apoliprotein e.g. ApoCIII that has at least one of the following activities: (a) the inhibition of the binding of Apolipoprotein B to its receptor, and, or, (b) the inhibition of lipoprotein lipase.